Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

ATHA
Athira Pharma, Inc. Common Stock
stock NASDAQ

At Close
May 8, 2025 3:59:54 PM EDT
0.2600USD+10.478%(+0.0250)92,400
0.00Bid   0.00Ask   0.0000Spread
Pre-market
May 7, 2025 9:01:30 AM EDT
0.2525USD+5.826%(+0.0139)0
After-hours
Dec 31, 1969 7:00:00 PM EST
0.00USD0.000%(0.00)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
07:00AM EST  Athira Pharma Announces Appointment of Grant Pickering to its   GlobeNewswire Inc
Jan 25, 2022
07:12AM EST  Athira Pharma Announces Initiation Of Patient Dosing In SHAPE, A Phase 2 Clinical Trial Of ATH-1017 For Treatment Of Parkinson's Disease Dementia And Dementia With Lewy Bodies   Benzinga
07:00AM EST  Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a   GlobeNewswire Inc
Jan 5, 2022
07:31AM EST  NUBIAN AND ATHENA ANNOUNCE CLOSING OF SALE AND ACQUISITION OF EXCELSIOR SPRINGS   PR Newswire
07:21AM EST  Athira Pharma Provides 2022 Pipeline Outlook   Benzinga
07:00AM EST  Topline data from ACT-AD Phase 2 Alzheimers disease study in 2Q22   GlobeNewswire Inc
Dec 15, 2021
10:05AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021   Benzinga
06:24AM EST  Goldman Sachs Initiates Coverage On Athira Pharma with Neutral Rating, Announces Price Target of $16   Benzinga
Nov 10, 2021
05:45PM EST  Athira Pharma Q3 EPS $(0.42) Up From $(1.12) YoY   Benzinga
11:50AM EST  Balanced baseline characteristics in ACT-AD and LIFT-AD to date Topline data from ACT-AD trial targeted for first half of 2022   GlobeNewswire Inc
Nov 8, 2021
07:00AM EST  -Stifel 2021 Virtual Healthcare Conference--Jefferies 2021 London Healthcare Conference-   GlobeNewswire Inc
Oct 29, 2021
07:00AM EDT  -- Neurologist Dr. John Michael Olichney to discuss utility of P300 to assess cognitive function -- Webinar to be held Friday, Nov. 5, at 9 a.m. PT / 12 p.m. ET   GlobeNewswire Inc
Oct 22, 2021
08:30AM EDT  Athira Pharma Announces Completion Of Enrollment In Phase 2 ACT-AD Trial Evaluating ATH-1017 For Mild-To-Moderate Alzheimer's Disease   Benzinga
08:23AM EDT  Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD   GlobeNewswire Inc
07:36AM EDT  The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs   Benzinga
Oct 21, 2021
04:17PM EDT  Athira Pharma Appoints Mark Litton, Ph.D., M.B.A. As CEO And Rachel Lenington As COO   Benzinga
04:05PM EDT  -- Special Committee of the Board of Directors has concluded its investigation of Dr. Leen Kawass Doctoral Research -- Conference call to be held October 21, 2021 at 4:30 pm ET   GlobeNewswire Inc
Oct 5, 2021
09:15AM EDT  Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases   Benzinga
Sep 29, 2021
08:17AM EDT  Athira Pharma To Present Updates From Phase 2/3 Trials Of ATH-1017 At 2021 Clinical Trials On Alzheimer's Disease (CTAD) Conference Nov. 10   Benzinga
08:06AM EDT  Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017   GlobeNewswire Inc
Aug 23, 2021
07:45PM EDT  KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuits Against Athira Pharma, Inc. - ATHA   PR Newswire
02:43PM EDT  Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for Athira Pharma, Inc. Investors - ATHA   Business Wire
07:35AM EDT  Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer's Disease Summit   Benzinga
07:31AM EDT  Athira Pharma to Present on ERP P300 as a Direct, Functional,   GlobeNewswire Inc
Aug 21, 2021
01:57PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Athira Pharma, Inc. (Athira or the Company) (NASDAQ:ATHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
11:51AM EDT  Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims.   GlobeNewswire Inc
Aug 20, 2021
10:50PM EDT  ATHIRA PHARMA 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Athira Pharma, Inc. - ATHA   Business Wire
02:14PM EDT  ATHA DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP   GlobeNewswire Inc
10:00AM EDT  ATHA, RKT & REKR Class Action Deadline Reminders: Bronstein,   GlobeNewswire Inc
Aug 19, 2021
01:14PM EDT  DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Athira   PR Newswire
Aug 18, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
10:36PM EDT  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 16, 2021
10:50PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
04:04PM EDT  Athira Pharma Q2 EPS $(0.38) Up From $(0.48) YoY   Benzinga
04:01PM EDT  - Initiated open label extension for LIFT-AD and ACT-AD trials of ATH-1017 allowing for an additional six months of treatment   GlobeNewswire Inc
10:07AM EDT  ATHA EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces   GlobeNewswire Inc
09:36AM EDT  Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims.   GlobeNewswire Inc
Aug 13, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Aug 11, 2021
01:18PM EDT  Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Athira   PR Newswire
Aug 10, 2021
02:42PM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
Aug 9, 2021
11:51AM EDT  Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims.   GlobeNewswire Inc
Aug 8, 2021
06:35PM EDT  Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder   GlobeNewswire Inc
Aug 6, 2021
10:50PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Aug 5, 2021
06:29PM EDT  Athira Pharma Mourns the Loss of Chair of Board of Directors, Tadataka Yamada, M.D.   Benzinga
Aug 3, 2021
07:11PM EDT  CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Athira Pharma,   PR Newswire
Aug 2, 2021
10:50PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
01:46PM EDT  Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims.   GlobeNewswire Inc
Jul 31, 2021
10:04AM EDT  ATHA Reminder: Kessler Topaz Meltzer & Check, LLP - Deadline   GlobeNewswire Inc
Jul 30, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
12:22PM EDT  Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating claims of violations of federal securities laws on behalf of investors of Athira Pharma, Inc. (Athira or the Company) (NASDAQ: ATHA). If you are a shareholder of Athira with more than $50,000 in losses, you should contact the Firm.   GlobeNewswire Inc
Jul 26, 2021
03:22PM EDT  Deadline in Securities Fraud Class Action Lawsuit Filed Against Athira Pharma, Inc.   PR Newswire
01:45PM EDT  Pomerantz LLP is investigating claims on behalf of investors of. Athira Pharma, Inc. (Athira or the Company) (NASDAQ:ATHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
12:18PM EDT  Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims.   GlobeNewswire Inc
Jul 25, 2021
10:05AM EDT  The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More   Benzinga
Jul 23, 2021
10:50PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
09:45AM EDT  Kessler Topaz Meltzer & Check, LLP: Final Deadline Reminder for   GlobeNewswire Inc
Jul 22, 2021
12:35PM EDT  Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating claims of violations of federal securities laws on behalf of investors of Athira Pharma, Inc. (Athira or the Company) (NASDAQ: ATHA). If you are a shareholder of Athira with more than $50,000 in losses, you should contact the Firm.   GlobeNewswire Inc
Jul 20, 2021
10:50PM EDT  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
07:00PM EDT  Athira Pharma, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit   PR Newswire
10:45AM EDT  Abraham, Fruchter & Twersky LLP announces the filing of a class action lawsuit on behalf of investors who purchased Athira Pharma, Inc. (Athira or the Company) (NASDAQ:ATHA) common stock between September 18, 2020 and June 17, 2021, or in connection with Athiras September 2020 initial public offering (IPO).   GlobeNewswire Inc
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 19, 2021
06:13PM EDT  Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating claims of violations of federal securities laws on behalf of investors of Athira Pharma, Inc. (Athira or the Company) (NASDAQ: ATHA). If you are a shareholder of Athira with more than $50,000 in losses, you should contact the Firm.   GlobeNewswire Inc
01:28PM EDT  Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims.   GlobeNewswire Inc
10:15AM EDT  Shareholder Alert: Kessler Topaz Meltzer & Check, LLP Reminds   GlobeNewswire Inc
07:04AM EDT  Athira Pharma To Present ATH-1017 Phase 1 Translational Data At Alzheimer's Association International Conference 2021 Jul. 26-30   Benzinga
07:00AM EDT  Athira Pharma to Present ATH-1017 Phase 1 Translational Data at   GlobeNewswire Inc
Jul 16, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Jul 15, 2021
09:02PM EDT  ATHA Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds   GlobeNewswire Inc
06:49PM EDT  Pomerantz LLP is investigating claims on behalf of investors of. Athira Pharma, Inc. (Athira or the Company) (NASDAQ:ATHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Jul 14, 2021
10:00PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Jul 13, 2021
10:40PM EDT  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
Jul 12, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
01:33PM EDT  ATHA INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline   PR Newswire
Jul 11, 2021
05:40PM EDT  Kessler Topaz Meltzer & Check, LLP Reminds Athira Pharma, Inc.   GlobeNewswire Inc
Jul 9, 2021
10:51PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Jul 7, 2021
11:43PM EDT  Pomerantz LLP is investigating claims on behalf of investors of. Athira Pharma, Inc. (Athira or the Company) (NASDAQ:ATHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
08:00PM EDT  Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action   GlobeNewswire Inc
Jul 6, 2021
06:22PM EDT  Class Action Alert: Kessler Topaz Meltzer & Check, LLP Reminds ATHA Investors   PR Newswire
09:36AM EDT  Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims.   GlobeNewswire Inc
09:09AM EDT  Athira Pharma Starts Open-Label Extension Of Alzheimer's Disease Trials   Benzinga
07:03AM EDT  Athira Pharma Announces Initiation Of Open Label Extension Study For LIFT-AD And ACT-AD Clinical Trials Of ATH-1017 For Alzheimer's Disease   Benzinga
07:00AM EDT  Athira Pharma Announces Initiation of Open Label Extension Study   GlobeNewswire Inc
Jul 3, 2021
01:14PM EDT  Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds   GlobeNewswire Inc
09:33AM EDT  Lead Plaintiff in Securities Fraud Class Action Lawsuit Against Athira Pharma - Contact Johnson Fistel   PR Newswire
Jun 30, 2021
05:25PM EDT  Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class   PR Newswire
09:35AM EDT  Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims.   GlobeNewswire Inc
Jun 29, 2021
08:00PM EDT  Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud   GlobeNewswire Inc
Jun 28, 2021
11:34PM EDT  Investors to Contact Firm's Attorneys Now, Securities Fraud Case Filed   PR Newswire
04:55PM EDT  Pomerantz LLP is investigating claims on behalf of investors of. Athira Pharma, Inc. (Athira or the Company) (NASDAQ:ATHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Jun 24, 2021
05:34PM EDT  Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations related to Athiras recent decision to place its CEO (Leen Kawas) on temporary leave.   GlobeNewswire Inc
Jun 23, 2021
09:36AM EDT  Investors to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations   PR Newswire
Jun 18, 2021
03:05PM EDT  Mid-Afternoon Market Update: Dow Tumbles Over 400 Points; CAI International Shares Spike Higher   Benzinga
01:10PM EDT  Washington State University to review claims of research misconduct   PR Newswire
12:18PM EDT  Mid-Day Market Update: Crude Oil Rises Over 1%; Orphazyme Shares Plunge   Benzinga
10:40AM EDT  Mid-Morning Market Update: Markets Open Lower; Adobe Reports Upbeat Q2 Earnings   Benzinga
07:46AM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
Jun 17, 2021
05:01PM EDT  Athira Pharma COO Mark Litton Assumes Day-To-Day Leadership Responsibilities Of Co   Benzinga
05:00PM EDT  Athira Pharma, Inc. (NASDAQ: ATHA) (Athira), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Mark Litton, PhD, MBA, in his capacity as Chief Operating Officer, has assumed day-to-day leadership responsibilities for the Company, effective immediately.   GlobeNewswire Inc
Jun 14, 2021
07:36AM EDT  Athira Pharma Names Rachel Lenington As Chief Technology Officer, Head Of Product Development Strategy   RTTNews
07:00AM EDT  Athira Pharma, Inc.(NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Rachel Lenington as Chief Technology Officer, Head of Product Development Strategy, effective June 14.   GlobeNewswire Inc
Jun 9, 2021
07:00AM EDT  Athira Pharma to Present at Upcoming Investor Conferences   GlobeNewswire Inc
Jun 7, 2021
12:23PM EDT  UPDATE: Jefferies On Athira Says 'FDA neuro division is becoming more flexible, supportive and conducive in getting neurology drugs approved...'   Benzinga
Jun 1, 2021
07:00AM EDT  Athira Pharma, Inc.(NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Mark Worthington as the companys General Counsel, effective June 1.   GlobeNewswire Inc
May 26, 2021
07:00AM EDT  - Jefferies Healthcare Conference- Goldman Sachs 42nd Annual Global Healthcare Conference   GlobeNewswire Inc
May 13, 2021
04:23PM EDT  Athira Pharma Q1 EPS $(0.25) Up From $(0.48) YoY   Benzinga
04:02PM EDT  -Phase 2 trial initiation for Parkinsons disease dementia program and IND submission for neuropsychiatric program planned by end of 2021-   GlobeNewswire Inc
Apr 21, 2021
07:00AM EDT  Athira Pharma to Participate in Panel Discussion at Sachs   GlobeNewswire Inc
Apr 8, 2021
07:00AM EDT  -- Featuring leading neurologist Marwan Sabbagh, M.D -- Webinar to be held Thursday, April 15, at 1:30 p.m. PT / 4:30 p.m. ET   GlobeNewswire Inc
Mar 25, 2021
04:04PM EDT  Athira Pharma Q4 EPS $(0.24) Up From $(0.27) YoY   Benzinga
04:02PM EDT  LIFT-AD and ACT-AD studies evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimers disease, actively enrolling patients   GlobeNewswire Inc
Mar 24, 2021
07:00AM EDT  Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at Stifels 3rd Annual CNS Conference on Thursday, April 1, 2021, at 9:00 am ET.   GlobeNewswire Inc
Mar 23, 2021
07:00AM EDT  Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that the company will participate in panel and corporate presentations at the virtual Life Science Innovation Northwest Conference taking place March 30-31, 2021.   GlobeNewswire Inc
Mar 8, 2021
07:12AM EST  Athira Pharma Appoints Barbara Kosacz To Board   RTTNews
07:00AM EST  Athira Pharma Announces Appointment of Barbara   GlobeNewswire Inc
Mar 2, 2021
07:00AM EST  Athira Pharma to Present at H.C. Wainwright & Co. Global Life   GlobeNewswire Inc
Feb 10, 2021
04:05PM EST  Athira Pharma Announces Exercise of Underwriters   GlobeNewswire Inc
Jan 30, 2021
11:10AM EST  Notable Insider Buys Seen In The Past Week: Green Brick, Intel, Teledyne And More   Benzinga
Jan 28, 2021
06:07AM EST  Athira Pharma 10%+ Owner Joseph Edelman Reported Purchase of 311,111 Shares @ Avg Price of $22.50/Share in Form 4 Filing on Wednesday   Benzinga
Jan 21, 2021
05:45AM EST  Athira Pharma Priced 4M Share Public Offering of Common Stock @$22.50/Share   Benzinga
Jan 20, 2021
07:57PM EST  Athira Pharma Prices Public Offering Of 4 Mln Shares At $22.50/shr   RTTNews
07:36PM EST  Athira Pharma Announces Pricing of Public Offering of Common Stock   GlobeNewswire Inc
Jan 19, 2021
08:00AM EST  Athira Pharma Announces Proposed Public Offering 4M Shares Of Common Stock   Benzinga
08:00AM EST  Athira Pharma Announces Proposed Public Offering of Common Stock   GlobeNewswire Inc
Jan 7, 2021
07:30AM EST  Athira Pharma to Present at the 39th Annual J.P. Morgan Healthcare   GlobeNewswire Inc
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 14, 2020
07:30AM EST  Athira Pharma Announces Appointment of Kelly A. Romano to its   GlobeNewswire Inc
Dec 8, 2020
07:34AM EST  Athira Pharma Awarded $15M Grant from the National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer's Disease   Benzinga
07:30AM EST  Athira Pharma Awarded $15 Million Grant from National Institute on   GlobeNewswire Inc
Dec 1, 2020
07:49AM EST  Athira Pharma Initiates Patient Dosing For ACT-AD Clinical Trial Of ATH-1017   RTTNews
07:36AM EST  Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimer's Disease   Benzinga
07:30AM EST  Athira Pharma Announces Initiation of Patient Dosing for ACT-AD   GlobeNewswire Inc
Nov 12, 2020
04:25PM EST  Athira Pharma Q3 EPS $(1.12) Down From $(0.43) YoY   Benzinga
04:05PM EST  - LIFT-AD clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimers disease, actively enrolling   GlobeNewswire Inc
Nov 10, 2020
07:30AM EST  Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Dr. Leen Kawas, President and Chief Executive Officer, and Dr. Hans Moebius, Chief Medical Officer, will participate in fireside chats at two upcoming investor conferences:   GlobeNewswire Inc
Nov 5, 2020
07:54AM EST  The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping   Benzinga
Oct 22, 2020
07:52AM EDT  The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat   Benzinga
Oct 21, 2020
08:04AM EDT  The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings   Benzinga
07:30AM EDT  - Expert neuropsychiatricclinician to discuss the testing method and its correlation to clinical results   GlobeNewswire Inc
Oct 20, 2020
08:17AM EDT  The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger   Benzinga
Oct 13, 2020
09:38AM EDT  Benzinga's Top Upgrades, Downgrades For October 13, 2020   Benzinga
06:38AM EDT  Jefferies Initiates Coverage On Athira Pharma with Buy Rating, Announces Price Target of $30   Benzinga
06:37AM EDT  JMP Securities Initiates Coverage On Athira Pharma with Market Outperform Rating   Benzinga
06:36AM EDT  Stifel Initiates Coverage On Athira Pharma with Buy Rating, Announces Price Target of $36   Benzinga
04:59AM EDT  Goldman Sachs Initiates Coverage On Athira Pharma with Buy Rating, Announces Price Target of $53   Benzinga
Oct 8, 2020
07:31AM EDT  Lumen Bioscience Announces Appointment of Dr. Mark Litton to Board of Directors   PR Newswire
Oct 1, 2020
07:44AM EDT  Athira Pharma Reports Initiation Of Patient Dosing For LIFT-AD Study   RTTNews
07:37AM EDT  Athira Pharma Initiates Patient Dosing For LIFT-AD Study, A Phase 2/3 Clinical Trial To Evaluate ATH-1017 For Treatment Of Mild-To-Moderate Alzheimer's Disease   Benzinga
07:30AM EDT  -Study to evaluate the safety and efficacy of ATH-1017 to improve mild-to-moderate Alzheimers disease-   GlobeNewswire Inc
Sep 22, 2020
04:05PM EDT  Athira Pharma Announces Closing of Initial Public Offering   GlobeNewswire Inc
Sep 18, 2020
12:01PM EDT  Athira Pharma Shares Open For Trade At $19.95; IPO Priced At $17/Share   Benzinga
12:00PM EDT  Still Waiting On 2 IPOs For Today: Athira Pharma (ATHA), Last Indicated At $20 After Pricing At $17/Share; COMPASS Pathways (CMPS), Last Indicated At $28 After Pricing At $17/Share   Benzinga
11:43AM EDT  Athira Pharma Shares Indicated $20 On 718K Shares   Benzinga
10:52AM EDT  Athira Pharma Shares Indicating $22 On 513K Shares   Benzinga
09:13AM EDT  Athira Pharma Expected To Open For Quote At 10:35 a.m. EDT, Expected To Open For Trade After 10:45 a.m. EDT; IPO Priced At $17/Share   Benzinga
04:17AM EDT  Athira Upsizes IPO, Looks To Raise Over $204M   Benzinga
Sep 17, 2020
08:49PM EDT  Athira Pharma Prices IPO Of 12 Mln Shares At $17.00/shr   RTTNews
08:22PM EDT  Athira Pharma Announces Pricing of Initial Public Offering   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC